Skip to main content
23965 search results for:

Glioblastoma 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 05-04-2024 | Glioblastoma | ReviewPaper

    Strategies to Improve Drug Delivery Across the Blood–Brain Barrier for Glioblastoma

    Glioblastoma remains resistant to most conventional treatments. Emerging therapies aim to overcome the challenges posed by the blood–brain barrier and tumor microenvironment.

  2. Free for a limited time 28-03-2024 | Glioblastoma | Online First

    Novel Clinical Trials and Approaches in the Management of Glioblastoma

    Recent clinical trials in glioblastoma have investigated a wide variety of therapeutic options, such as targeted agents, immunotherapies, and vaccine-based therapies. Find out more in this review.

  3. 01-12-2024 | Glioblastoma | Letter

    The implications of machine learning in predicting glioblastoma recurrence: a correspondence

  4. Open Access 15-04-2024 | Bevacizumab | OriginalPaper

    Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment

    Glioblastoma multiforme (GBM) acquires resistance to bevacizumab (Bev) treatment. Bev affects angiogenic factors other than vascular endothelial growth factor (VEGF), which are poorly understood. We investigated changes in angiogenic factors under …

  5. 01-12-2024 | OriginalPaper

    Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification

    Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system (CNS), accounting for 49.1% of all brain malignancies with an incidence of 3.23 cases per 100,000 [ 19 , 27 , 38 ].

  6. Open Access 19-04-2024 | Glioblastoma | Online First

    Personalized prognosis stratification of newly diagnosed glioblastoma applying a statistical decision tree model

    Glioblastoma (GBM) is the most aggressive glioma recurring on a regular basis despite extensive tumor treatment and usually resulting into a limited overall survival (OS) [ 1 ]. Although GBM is a clearly defined entity on a histological and …

  7. 15-04-2024 | Bevacizumab | Online First

    Preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed and resectable glioblastoma

  8. 01-12-2024 | Glioblastoma | ReviewPaper

    Laser interstitial thermal therapy for recurrent glioblastomas: a systematic review and meta-analysis

    We aim to investigate the efficacy and safety of laser interstitial thermal therapy (LITT) in treating recurrent glioblastomas (rGBMs). A comprehensive search was conducted in four databases to identify studies published between January 2001 and …

  9. Open Access 01-12-2024 | Photodynamic Therapy | ReviewPaper

    Beyond fluorescence-guided resection: 5-ALA-based glioblastoma therapies

    Glioblastoma is the most common primary malignant brain tumor. Despite advances in multimodal concepts over the last decades, prognosis remains poor. Treatment of patients with glioblastoma remains a considerable challenge due to the infiltrative …

  10. 23-02-2024 | Glioblastoma | Letter

    Harnessing imaging biomarkers for glioblastoma metastasis diagnosis: a correspondence

  11. Open Access 01-12-2024 | Glioblastoma | ReviewPaper

    Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review

    Glioblastoma (GBM) is a fatal brain tumour that is traditionally diagnosed based on histological features. Recent molecular profiling studies have reshaped the World Health Organization approach in the classification of central nervous system …

  12. Open Access 01-12-2024 | Glioblastoma | OriginalPaper

    Spatial transcriptomics reveals segregation of tumor cell states in glioblastoma and marked immunosuppression within the perinecrotic niche

    Glioblastoma (GBM) remains an untreatable malignant tumor with poor patient outcomes, characterized by palisading necrosis and microvascular proliferation. While single-cell technology made it possible to characterize different lineage of glioma …

  13. 18-04-2024 | Glioblastoma | Online First

    “Pushing the Envelope”: advanced imaging-data-analysis meets NODDI to differentiate glioblastoma and brain metastasis

  14. 26-03-2024 | Glioblastoma | Online First

    Glioblastoma stem cell metabolism and immunity

    Despite enormous efforts being invested in the development of novel therapies for brain malignancies, there remains a dire need for effective treatments, particularly for pediatric glioblastomas. Their poor prognosis has been attributed to the …

  15. 21-03-2024 | Glioblastoma | Online First

    Current approaches in glioblastoma multiforme immunotherapy

    Glioblastoma multiform (GBM) is the most prevalent CNS (central nervous system) tumor in adults, with an average survival length shorter than 2 years and rare metastasis to organs other than CNS. Despite extensive attempts at surgical resecting …

  16. 23-04-2024 | Glioblastoma | Online First

    Genomic landscape of glioblastoma without IDH somatic mutation in 42 cases: a comprehensive analysis using RNA sequencing data

    Glioblastoma (GBM) is the most aggressive malignant brain tumor with a median survival time of 15 months [ 1 ]. The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System classified primary GBM into IDH- …

  17. Open Access 24-04-2024 | Glioblastoma | Online First

    Correction to: Maximal cardiopulmonary exercise testing in glioblastoma patients undergoing chemotherapy: assessment of feasibility, safety, and physical fitness status

  18. 25-04-2024 | Glioblastoma | Online First

    Exploring the impact of primary care utilization and health information exchange upon treatment patterns and clinical outcomes of glioblastoma patients

    Glioblastoma (GBM) is the most common adult central nervous system malignancy [ 1 ]. GBM has an overall poor prognosis, which is reduced further by advanced age, frailty, and incomplete extent of surgical resection [ 2 ]. The landmark Stupp et al.

  19. 01-02-2024 | Etomidate | OriginalPaper

    Etomidate inhibits tumor growth of glioblastoma by regulating M1 macrophage polarization

    Glioblastoma (GBM) is a common primary central nervous system tumor. Although the multimodal integrated treatment for GBM has made great progress in recent years, the overall survival time of GBM is still short. Thus, novel treatments for GBM are …

  20. 01-12-2024 | Glioblastoma | Letter

    Does the role of non-coding RNA FAM131B-AS2 in glioblastoma go beyond the ATR pathway? A correspondence

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.